Lilly settles Alaska Zyprexa case for $15 million

Share this article:
Eli Lilly announced a $15 million settlement with the State of Alaska, which sued the company for allegedly withholding information about Zyprexa side effects.

Lilly admitted no wrongdoing. In a statement, Robert Armitage, SVP and general counsel, said: “While we had a strong defense, we agreed with the State that the best result for everyone is an amicable resolution. A trial always involves significant time and resources, especially a two-phase trial like this one that posed additional legal hurdles. A settlement helps us get back to what we want to focus on as a company: developing important new medications through research and partnerships with doctors and patients.”

In addition to the $15 million, Alaska secured an agreement that “will ensure that Alaska is treated as favorably as any other state that may settle with Lilly in the future over similar claims.” The Wall Street Journal reported that before the trial started, Lilly offered a $2 million settlement and the state sought close to $200 million.
Share this article:

Email Newsletters

More in News

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Fabry disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.

Five things for pharma marketers to know: Wednesday, August 20

Five things for pharma marketers to know: Wednesday, ...

Novartis explores the virtual care space, a court has dismissed a lawsuit against IPAB, Doctors Without Borders calls the Ebola outbreak "a complete disaster" and Pfizer becomes the first pharma ...